Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers...
Main Authors: | Michael A. Thompson, Martin K. Oaks, Maharaj Singh, Karen M. Michel, Michael P. Mullane, Husam S. Tarawneh, Angi Kraut, Kayla J. Hamm |
---|---|
Format: | Article |
Language: | English |
Published: |
Aurora Health Care
2017-08-01
|
Series: | Journal of Patient-Centered Research and Reviews |
Subjects: | |
Online Access: | http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1453&context=jpcrr |
Similar Items
-
Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study
by: Andinet Alemu, et al.
Published: (2017-04-01) -
Response to pneumococcal vaccination in multiple myeloma
by: Loïc Renaud, et al.
Published: (2019-07-01) -
Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma
by: I. O. Stoma
Published: (2021-01-01) -
Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture
by: Samer Al Hadidi, et al.
Published: (2017-03-01) -
Structural studies of immunoglobulin molecules : the Fv fragment of mouse myeloma protein M315
by: Rose, David Richard
Published: (1981)